611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
When Is It Time for a Knee Replacement?AHA News: Death Rates From Tears In This Major Heart Artery Are Rising, Especially Among Women, Black AdultsOmicron COVID Causing Severe Croup in Young Children'Zapping' Air Passages May Bring Relief for Severe AsthmaModerna Asks FDA to Approve Second Booster for All AdultsNew Tick-Borne Virus Is Spreading Across U.S.Memory Issues Plague Long COVID PatientsCOVID Vaccine Won't Cause Rare Neuro Events, But COVID Infection CouldTriglycerides a Stroke Danger, Even With Statin TreatmentIt Can Take Weeks for Some Patients With Severe COVID to Recover ConsciousnessOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaBreathing Dirty Air Could Raise Your Odds for Rheumatoid ArthritisPalliative Care Crucial After Severe Stroke, But Many Patients Miss OutMammograms Can Also Highlight Heart Risks: StudyPfizer Asks FDA to Approve Second Booster for SeniorsEven a Little Light in Your Bedroom Could Harm HealthMental Issues Can Linger More Than a Year After Severe COVIDRise in U.K. COVID Cases Closely Watched by U.S. Health OfficialsLong COVID May Bring Long-Term Lung DamageNew Malaria Treatment Gets First Approval for Use in ChildrenWarming World Means More Cases of Dangerous Low-Salt ConditionAbout 1 in 6 U.S. Couples Disagrees on COVID VaccinationCOVID Meds Appear to Work Against BA.2 Omicron Variant‘Deltacron’ Variant Rare and Not a Major ConcernCould Depression Make Dry Eye Worse?When Will Americans With Diabetes Get Relief From High Insulin Prices?COVID's Global Death Toll May Be 3 Times Official NumbersDrug Could Be Non-Antibiotic Alternative to Treat UTIsFlu Vaccine No Match for Circulating Variants This SeasonLymphedema in Legs Strikes 1 in 3 Female Cancer SurvivorsScience Brings Shortcut to Spotting 50 Rare Genetic DiseasesU.S. Airplane, Train and Transit Mask Mandates Extended to April 18Man Who Received First Pig Heart Transplant Has DiedPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Could a Stool Test Help Spot Pancreatic Cancer?Upcoming Surgery Worry You? Poll Says You're Not AloneHalf of Americans Live With Legacy of Childhood Lead PoisoningIn Reversal, WHO Now Supports COVID BoostersLooking to Neanderthals to Explain Today's Lower Back PainWhat's More Accurate, Blood Pressure Readings at Home or Doctor's Office?Begin Now to Protect Your Heart as Clocks 'Spring Forward'Brain Changes May Fuel 'Long COVID' Anxiety, ConfusionAHA News: Break Up Binge-Watching by Taking a StandHow COVID-19 Can Change the BrainHeart Defects Could Raise Odds for Severe COVID-196 Healthy Steps to Preventing Colon CancerAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesU.S. Surgeon General Investigates COVID-19 MisinformationLong or Irregular Periods May Put a Woman's Liver at RiskCould Your Blood Type Make COVID Worse?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

COVID Rapid Test Makers Struggling to Meet Demand

HealthDay News
by Robert Preidt and Robin Foster
Updated: Jan 21st 2022

new article illustration

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Shortages of both supplies and workers are wreaking havoc on the efforts of COVID at-home test makers to deliver enough of the tests to Americans, even as the federal government pledges to provide 500 million free, at-home kits.

Like many other businesses, test kit manufacturers "have too many of their staff out with COVID. Thus, even if they have the physical capacity for production, they don’t have the staff," Mara Aspinall, from Arizona State University, and colleagues wrote in a newsletter, NBC News reported.

She estimated that the current total monthly capacity of U.S. rapid at-home test kit manufacturing is 260 million units per month, which is expected to rise to 355 million by February and 526 million by March.

The government's order for the free test kits is in addition to existing supply and doesn't interfere with existing orders, said a senior White House official, who added that four new rapid tests with high-volume production capacity have been authorized since September, NBC News reported.

On Jan. 13, the Department of Defense announced the awarding of contracts to three companies, Abbott, Roche Diagnostics and iHealth labs, for 380 million test kits, in an “effort that supports the president’s plan to deliver 500 million free at-home COVID-19 tests."

Abbott has plans to “build two new U.S. manufacturing facilities, hired thousands of people for new jobs that pay American wages, and we continue to invest in automation to allow us to scale further,” Kim Modory, Abbott’s senior director of public affairs for diagnostics, told NBC News.

Abbott is currently producing 70 million tests a month. It is building up the ability to manufacture an additional 30 million to be added to support government, school and more retail efforts, Modory added.

Meanwhile, Roche spokeswoman Michelle Johnson said the company will start deliveries in January and by March provide “tens of millions” of test kits. The company has invested $500 million globally to boost instrument and test machine capacity. Still, “like other companies, we’ve experienced our share of supply challenges,” she said.

One of those other companies includes San Diego-based Quidel, which currently produces more than 40 million tests a month and plans to increase that to 70 million by February. Unfortunately, 10% of its workforce is currently quarantined.

“With Omicron, it’s gone crazy. The demand far exceeds what we’re doing,” Quidel CEO Douglas Bryant told NBC News. “The biggest challenge is actually enough people to do the work."

Bryant said the company has found it difficult to reach its target of hiring 400 workers for a new production facility and finding enough trucks to make deliveries, NBC News reported.

Supplies are also an issue: Demand for high-quality nitrocellulose membrane, the off-white fabric that forms the COVID test strip, has soared during the pandemic.

Some manufacturers cited difficulties sourcing sufficient nitrocellulose supplies a an obstacle to production earlier this year, a senior administration official told NBC News.

"We acted to alleviate" the bottleneck, the official said.

In a statement, Rachel Bloom-Baglin, a spokesperson for MilliporeSigma, a supplier of nitrocellulose to major U.S. rapid test kit makers, told NBC News that “raw material availability to make nitrocellulose membrane is readily available, but the world does not have enough membrane manufacturing capacity to turn the raw materials into finished goods, which are then used by our customers to manufacture rapid antigen tests."

The company makes the product at a facility in Cork, Ireland. Although the company completed an expansion of the plant that doubled its capacity, even that did not meet the soaring demand.

On Dec. 29, the Department of Defense awarded a $136.7 million contract to MilliporeSigma for the construction of a new facility in Sheboygan, Wisconsin, over a three-year timespan, NBC News reported.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID tests.


SOURCE: NBC News